ArticleBlood cancer discovery2025
CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells.
Abstract read
In one paragraph
Article in Blood cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Preclinical advances and mechanistic insights of CAR-T therapy for acute myeloid leukemia: from target iteration to microenvironment regulation.Annals of medicine · 2026Review
- Review
- Pediatric AML CAR T cell therapy.Molecular therapy. Oncology · 2026Review
- Advancements in delivery systems for in vivo chimeric antigen receptor T-cell therapy in urological diseases.Current urology · 2026Review
- Exploring CAR cell therapies beyond CAR-T for myeloid malignancies.Journal of biomedical science · 2026Review
- Enhancing persistence while managing cytokine release syndrome to embrace next-generation CAR-T cell therapy.Journal of translational medicine · 2026Review
- Engineering CAR-T cells for solid tumors: overcoming antigenic, trafficking, and microenvironmental barriers.Frontiers in immunology · 2026Review
- Review
- Have CARs stalled for non-B-cell malignancies? Where are we, and where are we going?Hematology. American Society of Hematology. Education Program · 2025Review
- Emerging strategies in CAR-T cell therapy for acute myeloid leukemia: overcoming heterogeneity and improving safety through dual-antigen targeting.Experimental hematology & oncology · 2025Review
- Effective imaging and treatment of Acute Myeloid Leukemia with radiotheranostics targeting the activated conformation of integrin-βeta2.Research square · 2025Article
- Strategic innovations: Tackling challenges of immunotherapy in acute myeloid leukemia.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.Journal of hematology & oncology · 2025Review
- Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies.Cancer cell international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Samy JambonDivision of Hematology and Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0001-7236-3239
Jianping SunDivision of Hematology and Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0009-0001-1987-5814
Shawn BarmanDivision of Hematology and Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0003-0008-2811
Sakunthala MuthugounderDivision of Hematology and Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0009-0003-5493-7245
Xue Rachel BitoDivision of Hematology and Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0009-0008-1034-9843
Armita ShadfarDivision of Hematology and Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0009-0004-1646-6443
Alexandra E KovachDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0002-6742-6749
Brent L WoodDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0001-7414-3969
Varsha Thoppey ManoharanDepartment of Biochemistry and Molecular Biology, University of Calgary, Calgary, Canada.ORCID 0009-0009-6547-2221
A Sorana MorrissyDepartment of Biochemistry and Molecular Biology, University of Calgary, Calgary, Canada.ORCID 0000-0001-8526-562X
Deepa BhojwaniDivision of Hematology and Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0002-7559-7927
Alan S WayneDivision of Hematology and Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0001-9952-459X
Michael A PulsipherDivision of Hematology and Oncology, Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah.ORCID 0000-0003-3030-8420
Yong-Mi KimDivision of Hematology and Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0003-3793-6438
Shahab AsgharzadehDivision of Hematology and Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0002-0510-3848
Chintan ParekhDivision of Hematology and Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0001-8100-9151
Babak MoghimiDivision of Hematology and Oncology, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California.ORCID 0000-0002-5154-832X
Funding
Understanding the niche of minimal residual disease leukemia cellsR01CA172896 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KIM, YONG-MI · 2013 to 2022
$3.7MCouples Against LeukemiaCureSearch for Children's Cancer (CSCC)Hyundai Hope On Wheels (Hope On Wheels)NCI NIH HHS R01 CA172896Saban Research Institute (The Saban Research Institute)St. Baldrick's Foundation (SBF)University of Southern California (SC)
Abstract
significanceOur study demonstrates the use of "IF-THEN" SynNotch-gated CAR-T cells targeting CD33 and CD123 in AML reduces off-tumor toxicity. This strategy enhances T-cell phenotype, improves expansion, preserves HSPCs, and mitigates cytokine release syndrome-addressing critical limitations of existing AML CAR-T therapies.
Indexed as
Immunotherapy, AdoptiveInterleukin-3 Receptor alpha SubunitLeukemia, Myeloid, AcuteReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 3AnimalsHumansPhenotypeT-LymphocytesCD33 protein, humanIL3RA protein, humanInterleukin-3 Receptor alpha SubunitReceptors, Chimeric AntigenSialic Acid Binding Ig-like Lectin 3
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.